The goal of combined pharmacological approaches in the treatment of the acute radiation syndrome (ARS) is to obtain an effective therapy producing a minimum of undesirable side effects. This review summarizes important data from studies evaluating the efficacy of combining radioprotective agents developed for administration prior to irradiation and therapeutic agents administered in a post-irradiation treatment regimen. Many of the evaluated results show additivity, or even synergism, of the combined treatments in comparison with the effects of the individual component administrations. It can be deduced from these findings that the research in which combined treatments with radioprotectors/radiomitigators are explored, tested, and evaluated is well-founded. The requirement for studies highly emphasizing the need to minimize undesirable side effects of the radioprotective/radiomitigating therapies is stressed.

• Klíčová slova
• acute radiation syndrome, combined treatment, cytokines, radiomitigators, radioprotectors,
• MeSH
• akutní radiační syndrom farmakoterapie   metabolismus   patofyziologie   prevence a kontrola   MeSH
• amifostin terapeutické užití   MeSH
• dinoproston terapeutické užití   MeSH
• experimentální radiační poranění farmakoterapie   metabolismus   patofyziologie   MeSH
• faktor stimulující kolonie granulocytů terapeutické užití   MeSH
• fixní kombinace léků MeSH
• lidé MeSH
• metformin terapeutické užití   MeSH
• misoprostol terapeutické užití   MeSH
• radioprotektivní látky terapeutické užití   MeSH
• rozvrh dávkování léků MeSH
• synergismus léků MeSH
• vitamin E terapeutické užití   MeSH
• zvířata MeSH
• Check Tag
• lidé MeSH
• zvířata MeSH
• Publikační typ
• časopisecké články MeSH
• přehledy MeSH
• Názvy látek
• amifostin MeSH
• dinoproston MeSH
• faktor stimulující kolonie granulocytů MeSH
• fixní kombinace léků MeSH
• metformin MeSH
• misoprostol MeSH
• radioprotektivní látky MeSH
• vitamin E MeSH

Adenosine A3 receptor knockout (A3AR KO) mice and their wild-type (WT) counterparts were compared from the point of view of their abilities to survive exposures to lethal doses of γ-radiation belonging to the range of radiation doses inducing the bone marrow acute radiation syndrome. Parameters of cumulative 30-day survival (experiment using a midlethal radiation dose) or cumulative 11-day survival (experiment using an absolutely lethal radiation dose), and of mean survival time were evaluated. The values of A3AR KO mice always reflected their higher survival in comparison with WT ones, the P values being above the limit for statistical significance after the midlethal radiation dose and standing for statistical significance after the absolutely lethal radiation dose. This finding was considered surprising, taking into account the previously obtained findings on defects in numbers and functional properties of peripheral blood cells in A3AR KO mice. Therefore, previous hematological analyses of A3AR KO mice were supplemented in the present studies with determination of serum levels of the granulocyte colony-stimulating factor, erythropoietin, and thrombopoietin. Though distinct differences in these parameters were observed between A3AR KO and WT mice, none of them could explain the relatively high postirradiation survival of A3AR KO mice. Further studies on these mice comprising also those on other than hemopoietic tissues and organs can help to clarify their relative radioresistance.

• MeSH
• akutní radiační syndrom genetika   metabolismus   mortalita   MeSH
• míra přežití MeSH
• myši knockoutované MeSH
• myši MeSH
• receptor adenosinový A3 genetika   metabolismus   MeSH
• zvířata MeSH
• Check Tag
• myši MeSH
• zvířata MeSH
• Publikační typ
• časopisecké články MeSH
• práce podpořená grantem MeSH
• Názvy látek
• receptor adenosinový A3 MeSH

This article concisely summarizes data on the action of one of the principal and best known growth factors, the granulocyte colony-stimulating factor (G-CSF), in a mammalian organism exposed to radiation doses inducing acute radiation syndrome. Highlighted are the topics of its real or anticipated use in radiation accident victims, the timing of its administration, the possibilities of combining G-CSF with other drugs, the ability of other agents to stimulate endogenous G-CSF production, as well as of the capability of this growth factor to ameliorate not only the bone marrow radiation syndrome but also the gastrointestinal radiation syndrome. G-CSF is one of the pivotal drugs in the treatment of radiation accident victims and its employment in this indication can be expected to remain or even grow in the future.

• MeSH
• akutní radiační syndrom farmakoterapie   patologie   MeSH
• časové faktory MeSH
• faktor stimulující kolonie granulocytů biosyntéza   terapeutické užití   MeSH
• interleukin-3 terapeutické užití   MeSH
• kombinovaná farmakoterapie MeSH
• kostní dřeň patologie   účinky záření   MeSH
• lidé MeSH
• membránové proteiny terapeutické užití   MeSH
• rekombinantní proteiny terapeutické užití   MeSH
• rozvrh dávkování léků MeSH
• růstový faktor kmenových buněk terapeutické užití   MeSH
• thrombopoetin terapeutické užití   MeSH
• únik radioaktivních látek MeSH
• zvířata MeSH
• Check Tag
• lidé MeSH
• zvířata MeSH
• Publikační typ
• časopisecké články MeSH
• práce podpořená grantem MeSH
• přehledy MeSH
• Názvy látek
• faktor stimulující kolonie granulocytů MeSH
• flt3 ligand protein MeSH Prohlížeč
• interleukin-3 MeSH
• membránové proteiny MeSH
• rekombinantní proteiny MeSH
• růstový faktor kmenových buněk MeSH
• thrombopoetin MeSH

There exists a requirement for drugs which would be useful in therapy of an acute radiation damage of a mammalian organism. The aim of the study was to evaluate survival parameters in mice exposed to a lethal γ-ray dose of 8.5 Gy and treated with single doses of an adenosine A(3) receptor agonist, IB-MECA, or a cyclooxygenase-2 (COX-2) inhibitor, meloxicam, administered alone or in a combination early after irradiation, i.e., 0.5 and 1 h post-irradiation, respectively. The assessed parameters were the mean survival time (MST) and the cumulative percentage 30-day survival (CPS). Administrations of single intraperitoneal doses of either IB-MECA 0.5 h post-irradiation or meloxicam 1 h post-irradiation resulted in statistically significant increases of MST in comparison with the control irradiated mice. Combined administration of IB-MECA and meloxicam was found to be the only treatment statistically enhancing the parameter of CPS and to lead to the most expressive increase in MST of the experimental mice. The findings add new knowledge on the action of an adenosine A3 receptor agonist and a COX-2 inhibitor in an irradiated mammalian organism and suggest the potential of both the investigated drugs in the treatment of the acute radiation damage.

• MeSH
• adenosin analogy a deriváty   farmakologie   MeSH
• agonisté adenosinového receptoru A3 farmakologie   MeSH
• časové faktory MeSH
• celotělové ozáření škodlivé účinky   MeSH
• cyklooxygenasa 2 metabolismus   MeSH
• inhibitory cyklooxygenasy 2 farmakologie   MeSH
• lékové interakce MeSH
• meloxikam MeSH
• míra přežití MeSH
• myši MeSH
• radioprotektivní látky farmakologie   MeSH
• receptor adenosinový A3 metabolismus   MeSH
• thiaziny farmakologie   MeSH
• thiazoly farmakologie   MeSH
• záření gama škodlivé účinky   MeSH
• zvířata MeSH
• Check Tag
• mužské pohlaví MeSH
• myši MeSH
• zvířata MeSH
• Publikační typ
• časopisecké články MeSH
• práce podpořená grantem MeSH
• Názvy látek
• adenosin MeSH
• agonisté adenosinového receptoru A3 MeSH
• cyklooxygenasa 2 MeSH
• inhibitory cyklooxygenasy 2 MeSH
• meloxikam MeSH
• N(6)-(3-iodobenzyl)-5'-N-methylcarboxamidoadenosine MeSH Prohlížeč
• radioprotektivní látky MeSH
• receptor adenosinový A3 MeSH
• thiaziny MeSH
• thiazoly MeSH

The question as to whether A3 adenosine receptor (A3AR) agonists, N (6)-(3-iodobenzyl)-adenosine-5'-N- methyluronamide (IB-MECA) and 2-chloro-N (6)-(3-iodobenzyl)-adenosine-5'-N-methyluronamide (Cl-IB-MECA), could exert cytotoxic effects at high concentrations with or without the involvement of A3AR has been a controversial issue for a long time. The initial findings suggesting that A3AR plays a crucial role in the induction of cell death upon treatment with micromolar concentrations of IB-MECA or Cl-IB-MECA were revised, however, the direct and unequivocal evidence is still missing. Therefore, the sensitivity of Chinese hamster ovary (CHO) cells transfected with human recombinant A3AR (A3-CHO) and their counter partner wild-type CHO cells, which do not express any of adenosine receptors, to micromolar concentrations of IB-MECA and Cl-IB-MECA was studied. We observed that IB-MECA and Cl-IB-MECA exhibited a strong inhibitory effect on cell proliferation due to the blockage of cell cycle progression at G1/S and G2/M transitions in both A3-CHO and CHO cells. Further analysis revealed that IB-MECA and Cl-IB-MECA attenuated the Erk1/2 signalling irrespectively to A3AR expression. In addition, Cl-IB-MECA induced massive cell death mainly with hallmarks of a necrosis in both cell lines. In contrast, IB-MECA affected cell viability only slightly independently of A3AR expression. IB-MECA induced cell death that exhibited apoptotic hallmarks. In general, the sensitivity of A3-CHO cells to micromolar concentrations of IB-MECA and Cl-IB-MECA was somewhat, but not significantly, higher than that observed in the CHO cells. These results strongly suggest that IB-MECA and Cl-IB-MECA exert cytotoxic effects at micromolar concentrations independently of A3AR expression.

• MeSH
• adenosin analogy a deriváty   farmakologie   MeSH
• agonisté adenosinového receptoru A3 farmakologie   MeSH
• CHO buňky MeSH
• Cricetulus MeSH
• cytotoxiny farmakologie   MeSH
• kontrolní body buněčného cyklu účinky léků   MeSH
• lidé MeSH
• mitogenem aktivovaná proteinkinasa 1 antagonisté a inhibitory   genetika   metabolismus   MeSH
• mitogenem aktivovaná proteinkinasa 3 antagonisté a inhibitory   genetika   metabolismus   MeSH
• proliferace buněk účinky léků   MeSH
• protoonkogenní proteiny c-akt genetika   metabolismus   MeSH
• receptor adenosinový A3 genetika   metabolismus   MeSH
• regulace genové exprese MeSH
• signální transdukce účinky léků   MeSH
• transfekce MeSH
• viabilita buněk účinky léků   MeSH
• vztah mezi dávkou a účinkem léčiva MeSH
• zvířata MeSH
• Check Tag
• lidé MeSH
• zvířata MeSH
• Publikační typ
• časopisecké články MeSH
• práce podpořená grantem MeSH
• Názvy látek
• 2-chloro-N(6)-(3-iodobenzyl)adenosine-5'-N-methyluronamide MeSH Prohlížeč
• adenosin MeSH
• agonisté adenosinového receptoru A3 MeSH
• cytotoxiny MeSH
• MAPK1 protein, human MeSH Prohlížeč
• mitogenem aktivovaná proteinkinasa 1 MeSH
• mitogenem aktivovaná proteinkinasa 3 MeSH
• N(6)-(3-iodobenzyl)-5'-N-methylcarboxamidoadenosine MeSH Prohlížeč
• protoonkogenní proteiny c-akt MeSH
• receptor adenosinový A3 MeSH

The review summarizes data evaluating the role of adenosine receptor signaling in murine hematopoietic functions. The studies carried out utilized either non-selective activation of adenosine receptors induced by elevation of extracellular adenosine or by administration of synthetic adenosine analogs having various proportions of selectivity for a particular receptor. Numerous studies have described stimulatory effects of non-selective activation of adenosine receptors, manifested as enhancement of proliferation of cells at various levels of the hematopoietic hierarchy. Subsequent experimental approaches, considering the hematopoiesis-modulating action of adenosine receptor agonists with a high level of selectivity to individual adenosine receptor subtypes, have revealed differential effects of various adenosine analogs. Whereas selective activation of A₁ receptors has resulted in suppression of proliferation of hematopoietic progenitor and precursor cells, that of A₃ receptors has led to stimulated cell proliferation in these cell compartments. Thus, A₁ and A₃ receptors have been found to play a homeostatic role in suppressed and regenerating hematopoiesis. Selective activation of adenosine A₃ receptors has been found to act curatively under conditions of drug- and radiation-induced myelosuppression. The findings in these and further research areas will be summarized and mechanisms of hematopoiesis-modulating action of adenosine receptor agonists will be discussed.

• MeSH
• hematopoéza účinky léků   MeSH
• lidé MeSH
• purinergní receptory P1 účinky léků   MeSH
• signální transdukce MeSH
• zvířata MeSH
• Check Tag
• lidé MeSH
• zvířata MeSH
• Publikační typ
• časopisecké články MeSH
• práce podpořená grantem MeSH
• přehledy MeSH
• Názvy látek
• purinergní receptory P1 MeSH